2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Monday, October 22, 2018

9:00AM-11:00AM: Abstract Number: 1672

Poor Sleep Quality Predicts Worsening SLE Disease Activity

Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

9:00AM-11:00AM: Abstract Number: 1246

Practices of Hydroxychloroquine Dosing Based on the American Association of Ophthalmology (AAO) 2016 Recommendations: A Single Center Experience

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1502

Predicting Response to Methotrexate Therapy in New-Onset RA: No Value of Adding Protein Biomarkers to Clinical Predictors

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1137

Prediction Models for Poor Function Outcomes over 10 Years in Persons at High Risk for Knee Osteoarthritis

Epidemiology and Public Health Poster II: Gout, Ankylosing Spondylitis, Osteoarthritis, Osteoporosis, Pain, and Function

9:00AM-11:00AM: Abstract Number: 1788

Predictive Factors for Work-Day Loss in a Multi-Center Study in Behcet’s Disease: Indirect Costs for Healthcare

Vasculitis Poster II: Behҫet’s Disease and IgG4-Related Disease

9:00AM-11:00AM: Abstract Number: 1271

Predictive Factors of Increased Vascular Stiffness in Patient with Gout and Hyperuricemia

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 1361

Predictive Modeling of Therapeutic Response in Knee Osteoarthritis

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1373

Predictive Probabilities Are Superior in Communicating the Clinical Relevance of Cartilage Thickness As an Imaging Biomarker of Knee Osteoarthritis Progression

Osteoarthritis – Clinical Poster II

9:00AM-11:00AM: Abstract Number: 1507

Predictors of Fatigue and Persistent Fatigue in Early Rheumatoid Arthritis: A Longitudinal Observational Study

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1260

Predictors of Hospitalization Due to Acute Gout: A Retrospective Cohort Study

Measures and Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 1494

Predictors of Persistence to Methotrexate Treatment in RA – Assessment of Different Modelling Approaches

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1436

Pregnancy Outcomes in Partners of DMARD Exposed Men with Juvenile Idiopathic Arthritis – an Observational Study

Pediatric Rheumatology – Clinical Poster II: Autoinflammatory Disorders, Scleroderma, and Miscellaneous

9:00AM-11:00AM: Abstract Number: 1472

Preliminary Analysis of Genetic Variants in the Immune System Related to the Body Mass Index in Early Arthritis Patients

Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II: Diagnosis and Prognosis

9:00AM-11:00AM: Abstract Number: 1008

Presence of a Specific Defect in M2 Polarization of Blood Monocytes from Patients with Rheumatoid Arthritis, Associated with Increased microRNA-155

Innate Immunity Poster

9:00AM-11:00AM: Abstract Number: 1286

Pretreatment and Coadministration with Methotrexate Improved Durability of Pegloticase (Krystexxa) Response: A Prospective, Proof-of-Concept, Case Series

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].